Four pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
NuPathe Inc. (PATH) is bumping up its rating from a C (“hold”) to a B (“buy”) this week. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
Watson Pharmaceuticals (WPI) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This is a strong week for Mylan (MYL). The company’s rating climbs to A from the previous week’s B. Mylan is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.
The rating of Impax Laboratories, Inc. (IPXL) moves up this week, rising from a C to a B. Impax Laboratories develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of IPXL stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.